...year to refocus on its core complement inhibitor franchise plus marketed enzyme replacement therapies Strensiq asfotase alfa...
...Hematology Mary Romeo Kanuma, sebelipase alfa (sbc-102, rhLAL) Onpattro, patisiran (ALN-TTR02, GENZ438027, GZ438027, SAR438027) ravulizumab (ALXN1210) Soliris, eculizumab (5G1.1) Strensiq, asfotase alfa (ENB-0040) Alexion...

...year to refocus on its core complement inhibitor franchise plus marketed enzyme replacement therapies Strensiq asfotase alfa...
...Consensus figures provided by FactSet. Mary Romeo Kanuma, sebelipase alfa (sbc-102, rhLAL) ravulizumab (ALXN1210) Soliris, eculizumab (5G1.1) Strensiq, asfotase alfa (ENB-0040) Alexion...

...in August 2017 for Strensiq asfotase alfa to treat pediatric-onset hypophosphatasia. Like Translarna, the evaluation of Strensiq...
...agreement established a national committee of clinical experts to determine starting and stopping criteria for Strensiq...
...also includes the collection of data from every patient in England and Wales who receives Strensiq...

...upon approval of Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D) and Strensiq asfotase alfa...

...upon approval of Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D) and Strensiq asfotase alfa...

...FDA approved the company's Strensiq asfotase alfa to treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP) (see “Asfotase Alfa...

...which includes Soliris and its long-acting cousin ALXN1210 -- plus marketed enzyme replacement therapies Strensiq asfotase alfa...
...monophosphate (cPMP) replacement therapy (ALXN1101) Decuprate, bis-choline tetrathiomolybdate (WTX101, atn-224) Kanuma, sebelipase alfa (sbc-102, rhLAL) RhNAGLU (SBC-103) Strensiq, asfotase alfa (ENB-0040) Subcutaneous...

...in Phase III testing for PNH and aHUS, as well as enzyme replacement therapies Strensiq asfotase alfa...
...$1.4 billion in cash. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), New Haven, Conn. Business: Hematology, Endocrine/Metabolic, Autoimmune Mary Romeo ALXN1210 Kanuma Soliris Strensiq Alexion...

...in Phase III testing for PNH and aHUS, as well as enzyme replacement therapies Strensiq asfotase alfa...
...30, the company had $1.4 billion in cash. Alexion gained $1.14 to $144.07 on Tuesday. Mary Romeo ALXN1210 Kanuma Soliris Strensiq Alexion...

...syndrome (aHUS). Enzyme replacement therapies Strensiq asfotase alfa and Kanuma sebelipase alfa remain in the fold. Strensiq...